• 020 7251 3322
  • 226 Walmer Road, London W11 4ET

Erenumab (Aimovig™) now available within NHS Scotland

08 April 2019

The Scottish Medicines Consortium (SMC) announced today that Erunumab  ( Aimovig™) has been accepted for a restricted use within NHS Scotland for the treatment of chronic migraine.

We welcome this news and Dr David Bloomfield CEO of National Migraine Centre said: ”We are very pleased that SMC has approved the use of Erenumab (Aimovig™) for chronic migraine patients. This decision provides an additional preventative treatment option that will doubtless help many people.”


What is Aimovig™ ?

Aimovig™ a first-of-its-kind treatment specifically designed for migraine prevention, works by blocking the calcitonin gene-related peptide receptor (CGRP-R) that is known to be one of the neurochemicals involved in the transmission of migraine pain signals. This drug is manufactured by Novartis.

Aimovig™ is an injection.It can be self-administered or administered by another trained person every four weeks with the SureClick® autoinjector pen, an established device commonly used for a range of different conditions.


What is the restricted criteria?

The drug is available only for chronic migraine. The following is the restricted criteria that patient needs to meet to get the drug on NHS Scotland:

  • Patients who have more than 15 headache days a month, 8 of which are migraines.
  • Patient should have tried and failed at least three prior prophylactic treatments.

One of our Headache Specialist Dr Briscoe further explains the restricted criteria: ”We are delighted to hear that Erenumab (Aimovig™) has been approved for restricted use in NHS Scotland. As expected this is restricted to patients who suffer with chronic migraine (more than 15 headache days per month, 8 of which are migrainous) and for those who have tried and failed at least three prior preventatives. This puts it in a similar position to Botox. This is great news for patients who live in Scotland and have tried multiple treatments without success in the past and we hope that NICE will take this into consideration when they review their position on the use of Aimovig.”


What does this mean for you ?

If you live in Scotland and have chronic migraines then you could be eligible to be able to access the Aimovig on the NHS.

People who qualify under the restricted criteria laid out by the NHS Scotland should speak to their healthcare professional. If their healthcare professional thinks that Erenumab (Aimovig™)  is the right medicine for you, then you should be able to have that treatment on the NHS.

For more information click here or call us on 020 7251 3322.

At NMC our headache specialists can  prescribe Aimovig privately till it is available on the NHS across the UK. Book Now!